0001209191-23-056649.txt : 20231127 0001209191-23-056649.hdr.sgml : 20231127 20231127160941 ACCESSION NUMBER: 0001209191-23-056649 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20231127 FILED AS OF DATE: 20231127 DATE AS OF CHANGE: 20231127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Makunje Moses CENTRAL INDEX KEY: 0002001938 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39351 FILM NUMBER: 231440365 MAIL ADDRESS: STREET 1: C/O NUVATION BIO INC. STREET 2: 1500 BROADWAY, SUITE 1401 CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvation Bio Inc. CENTRAL INDEX KEY: 0001811063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850862255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 357 TEHAMA STREET, FLOOR 3 CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 754-3517 MAIL ADDRESS: STREET 1: 357 TEHAMA STREET, FLOOR 3 CITY: SAN FRANCISCO STATE: CA ZIP: 94103 FORMER COMPANY: FORMER CONFORMED NAME: Panacea Acquisition Corp DATE OF NAME CHANGE: 20200430 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-11-27 0 0001811063 Nuvation Bio Inc. NUVB 0002001938 Makunje Moses C/O NUVATION BIO INC. 1500 BROADWAY, SUITE 1401 NEW YORK NY 10036 0 1 0 0 See Remarks Class A Common Stock 10612 D Stock Option (Right to Buy) 1.74 2030-07-21 Class A Common Stock 112704 D Stock Option (Right to Buy) 4.60 2030-10-04 Class A Common Stock 112704 D Stock Option (Right to Buy) 5.06 2032-02-27 Class A Common Stock 291000 D Stock Option (Right to Buy) 2.93 2032-08-28 Class A Common Stock 233000 D Stock Option (Right to Buy) 1.94 2033-02-27 Class A Common Stock 194000 D Option vests as to 25% on the one year anniversary of 7/21/2020, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. The shares subject to the Option will vest based on the satisfaction of both time-based and performance-based vesting criteria. As of November 27, 2023, 22,540 of the shares subject to the Option have vested. Option vests as to 25% on the one year anniversary of 2/28/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Title: VP, Finance and principal financial and accounting officer. Moses Makunje, by /s/ Ron A. Metzger, Attorney-in-Fact. 2023-11-27 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Date: November 21, 2023 Know all by these presents, that the undersigned hereby constitutes and appoints David Hung of Nuvation Bio Inc. (the "Company") and Ron Metzger of Cooley LLP, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC; 2. execute for and on behalf of the undersigned with respect to the Company, Schedules 13D and 13G and Forms 3, 4, and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedules 13D or 13G or Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first written above. /s/ Moses Makunje